VRTX
Vertex Pharmaceuticals Incorporated
Set alert
558.88 USD +18.88 +3.50%
549.89 Day range 563.80
409.47 52-week range 558.88
- YTD
- +23.28%
- 1 year
- +33.10%
- Open
- 550.73
- Prev close
- 540.00
- Mkt cap
- 141.56B
- Vol
- 3.03M
- Avg vol
- 1.16M
- EPS
- 17.17
- P/E
- 32.55
- Div yield
- 0.00%
More statistics
- Low
- 549.89
- High
- 563.80
- Forward P/E
- 27.40
- Beta
- 0.28
- Short ratio
- 3.66
- Inst. own
- 98.16%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 522.84
- 200-d avg
- 478.67
- 1y target
- 571.46
Financial health
Altman Z-Score
14.11 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
5 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A-4 / 5 overall
- DCF 4
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 3
- P/E 2
- P/B 1
Valuation
P/E 29.3×
FY 2016 5y median 24.2× FY 2025
P/S 9.6×
FY 2016 5y median 9.4× FY 2025
P/B 6.2×
FY 2016 5y median 6.0× FY 2025
P/FCF 36.3×
FY 2016 5y median 23.5× FY 2025
EV/EBITDA 23.6×
FY 2016 5y median 20.7× FY 2025
EV/Sales 9.5×
FY 2016 5y median 9.2× FY 2025
FCF Yield 2.8%
FY 2016 5y median 3.1% FY 2025
Profitability
Gross Margin 85.0%
FY 2016 5y median 87.2% FY 2025
Operating Margin 39.4%
FY 2016 5y median 38.8% FY 2025
Net Margin 32.7%
FY 2016 5y median 32.7% FY 2025
ROE 21.2%
FY 2016 5y median 21.2% FY 2025
ROIC 18.1%
FY 2016 5y median 18.1% FY 2025
ROA 15.1%
FY 2016 5y median 15.9% FY 2025
Growth (YoY)
Revenue 9.6%
FY 2016 FY 2025
Operating Income 2144.1%
FY 2016 FY 2025
EPS (diluted) 836.5%
FY 2016 FY 2025
Free Cash Flow 504.1%
FY 2016 FY 2025
Financial Health
Current Ratio 2.9×
FY 2016 5y median 4.0× FY 2025
Quick Ratio 2.5×
FY 2016 5y median 3.8× FY 2025
Debt / Equity 0.2×
FY 2016 5y median 0.1× FY 2025
Net Debt / EBITDA -0.2×
FY 2016 5y median -2.1× FY 2025
Interest Coverage 358×
FY 2016 5y median 78.6× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31